Advertisement
Screener

KALA BIO, INC. (KALA) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

KALA BIO, INC. Stock-Based Compensation

KALA BIO, INC. (KALA) reported Stock-Based Compensation of -$607.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-19

  • KALA BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was -$136.00K, a 106.07% decline year-over-year.
  • KALA BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was -$471.00K, a 120.39% decline year-over-year.
  • KALA BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $401.00K, a 80.85% decline year-over-year.
  • KALA BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.04M, a 0.39% increase year-over-year.
  • KALA BIO, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $7.00M, a 16.62% decline from fiscal 2024.
  • KALA BIO, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $8.39M, a 12.41% increase from fiscal 2023.
  • KALA BIO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $7.46M, a 6.49% increase from fiscal 2022.
  • KALA BIO, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $7.01M, a 56.44% decline from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30-$136.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19
-$607.00K
10-Q · filed 2026-08-19
-$206.00K
derived: sum of 3 quarters · filed 2026-08-19
$1.84M
derived: sum of 4 quarters · filed 2026-08-19
2026-03-31-$471.00K
10-Q · filed 2026-05-15
-$70.00K
derived: sum of 2 quarters · filed 2026-05-15
$1.97M
derived: sum of 3 quarters · filed 2026-05-15
$4.21M
derived: sum of 4 quarters · filed 2026-08-19
2025-12-31$401.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$2.44M
derived: sum of 2 quarters · filed 2026-04-15
$4.68M
derived: sum of 3 quarters · filed 2026-08-19
$7.00M
10-K · filed 2026-04-15
2025-09-30$2.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
$4.28M
derived: sum of 2 quarters · filed 2026-08-19
$6.59M
10-Q · filed 2025-11-19
$8.69M
derived: sum of 4 quarters · filed 2026-08-19
2025-06-30$2.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19
$4.55M
10-Q · filed 2026-08-19
$6.64M
derived: sum of 3 quarters · filed 2026-08-19
$8.68M
derived: sum of 4 quarters · filed 2026-08-19
2025-03-31$2.31M
10-Q · filed 2026-05-15
$4.40M
derived: sum of 2 quarters · filed 2026-05-15
$6.44M
derived: sum of 3 quarters · filed 2026-05-15
$8.32M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$2.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$4.13M
derived: sum of 2 quarters · filed 2026-04-15
$6.01M
derived: sum of 3 quarters · filed 2026-04-15
$8.39M
10-K · filed 2026-04-15
2024-09-30$2.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
$3.92M
derived: sum of 2 quarters · filed 2025-11-19
$6.29M
10-Q · filed 2025-11-19
$8.67M
derived: sum of 4 quarters · filed 2025-11-19
2024-06-30$1.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08
$4.26M
10-Q · filed 2025-08-08
$6.63M
derived: sum of 3 quarters · filed 2025-08-08
$9.04M
derived: sum of 4 quarters · filed 2025-08-08
2024-03-31$2.38M
10-Q · filed 2025-05-14
$4.75M
derived: sum of 2 quarters · filed 2025-05-14
$7.15M
derived: sum of 3 quarters · filed 2025-05-14
$8.52M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$2.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$4.78M
derived: sum of 2 quarters · filed 2025-03-31
$6.14M
derived: sum of 3 quarters · filed 2025-03-31
$7.46M
10-K · filed 2025-03-31
2023-09-30$2.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$3.77M
derived: sum of 2 quarters · filed 2024-11-12
$5.09M
10-Q · filed 2024-11-12
$6.05M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$1.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$2.69M
10-Q · filed 2024-08-06
$3.65M
derived: sum of 3 quarters · filed 2024-08-06
$4.97M
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$1.32M
10-Q · filed 2024-05-14
$2.28M
derived: sum of 2 quarters · filed 2024-05-14
$3.61M
derived: sum of 3 quarters · filed 2024-05-14
$5.53M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$960.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$2.29M
derived: sum of 2 quarters · filed 2024-03-29
$4.20M
derived: sum of 3 quarters · filed 2024-03-29
$7.01M
10-K · filed 2024-03-29
2022-09-30$1.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$3.24M
derived: sum of 2 quarters · filed 2023-11-13
$6.05M
10-Q · filed 2023-11-13
$8.80M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$1.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
$4.72M
10-Q · filed 2023-08-04
$7.47M
derived: sum of 3 quarters · filed 2023-08-04
$11.40M
derived: sum of 4 quarters · filed 2023-08-04
2022-03-31$2.81M
10-Q · filed 2023-05-09
$5.55M
derived: sum of 2 quarters · filed 2023-05-09
$9.48M
derived: sum of 3 quarters · filed 2023-05-09
$14.19M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$2.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
$6.68M
derived: sum of 2 quarters · filed 2023-03-03
$11.39M
derived: sum of 3 quarters · filed 2023-03-03
$16.09M
10-K · filed 2023-03-03
2021-09-30$3.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$8.64M
derived: sum of 2 quarters · filed 2022-11-08
$13.34M
10-Q · filed 2022-11-08
$17.40M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$4.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$9.41M
10-Q · filed 2022-08-11
$13.47M
derived: sum of 3 quarters · filed 2022-08-11
$17.45M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$4.70M
10-Q · filed 2022-05-16
$8.77M
derived: sum of 2 quarters · filed 2022-05-16
$12.74M
derived: sum of 3 quarters · filed 2022-05-16
$15.52M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$4.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29
$8.04M
derived: sum of 2 quarters · filed 2022-03-29
$10.81M
derived: sum of 3 quarters · filed 2022-03-29
$13.31M
10-K · filed 2022-03-29
2020-09-30$3.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$6.75M
derived: sum of 2 quarters · filed 2021-11-15
$9.25M
10-Q · filed 2021-11-15
$11.57M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$2.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$5.27M
10-Q · filed 2021-08-05
$7.60M
derived: sum of 3 quarters · filed 2021-08-05
$10.17M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$2.50M
10-Q · filed 2021-05-05
$4.82M
derived: sum of 2 quarters · filed 2021-05-05
$7.39M
derived: sum of 3 quarters · filed 2021-05-05
$10.02M
derived: sum of 4 quarters · filed 2021-05-05
2019-12-31$2.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$4.90M
derived: sum of 2 quarters · filed 2021-02-25
$7.52M
derived: sum of 3 quarters · filed 2021-02-25
$9.99M
10-K · filed 2021-02-25
2019-09-30$2.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$5.19M
derived: sum of 2 quarters · filed 2020-11-05
$7.67M
10-Q · filed 2020-11-05
$9.86M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$2.62M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$5.09M
10-Q · filed 2020-08-06
$7.29M
derived: sum of 3 quarters · filed 2020-08-06
$9.56M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31$2.47M
10-Q · filed 2020-05-07
$4.67M
derived: sum of 2 quarters · filed 2020-05-07
$6.94M
derived: sum of 3 quarters · filed 2020-05-07
$9.23M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$2.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12
$4.46M
derived: sum of 2 quarters · filed 2020-02-12
$6.75M
derived: sum of 3 quarters · filed 2020-02-12
$8.62M
10-K · filed 2020-02-12
2018-09-30$2.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
$4.56M
derived: sum of 2 quarters · filed 2019-11-07
$6.42M
10-Q · filed 2019-11-07
$7.92M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30$2.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$4.15M
10-Q · filed 2019-08-06
$5.65M
derived: sum of 3 quarters · filed 2019-08-06
$6.63M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31$1.86M
10-Q · filed 2019-05-09
$3.36M
derived: sum of 2 quarters · filed 2019-05-09
$4.34M
derived: sum of 3 quarters · filed 2019-05-09
$4.91M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$1.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
$2.48M
derived: sum of 2 quarters · filed 2019-03-12
$3.05M
derived: sum of 3 quarters · filed 2019-03-12
$3.57M
10-K · filed 2019-03-12
2017-09-30$981.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$1.55M
derived: sum of 2 quarters · filed 2018-11-08
$2.07M
10-Q · filed 2018-11-08
$2.39M
derived: sum of 4 quarters · filed 2018-11-08
2017-06-30$567.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$1.09M
10-Q · filed 2018-08-09
$1.41M
derived: sum of 3 quarters · filed 2018-08-09
$1.97M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$522.00K
10-Q · filed 2018-05-10
$844.00K
derived: sum of 2 quarters · filed 2018-05-10
$1.40M
derived: sum of 3 quarters · filed 2018-05-10
2016-12-31$322.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02
$876.00K
derived: sum of 2 quarters · filed 2018-04-02
$2.07M
10-K · filed 2018-04-02
2016-09-30$554.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$1.75M
10-Q · filed 2017-11-07
2016-06-30$1.19M
10-Q · filed 2017-08-31
2015-12-31$638.00K
10-K · filed 2018-04-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
Moleculin Biotech, Inc. (MBRX)United States$0.011B
Theriva Biologics, Inc. (TOVX)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Dare Bioscience, Inc. (DARE)United States$0.011B
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92